



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Examiner:

DAVIS, Zinna Northington

K. Schoenafinger, et al

Art Unit:

1625

Application No.:

10/617,498

Filed:

July 11, 2003

Title:

**Heterocyclically Substituted** 

Benzoylureas, Process for Their Preparation

and Their use as Pharmaceuticals

Certificate of Mailing or Transmission

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop address below, or being facsimile transmitted to the

USPTO, on the date indicated below.

Date of Deposit May 20, 2005

Printed Name of Person Signing Certificate Bonnie Stein

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT FOR WHICH THE FEE SPECIFIED UNDER 37 C.F.R. 1.97(c) IS REQUIRED

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Enclosed is an Information Disclosure Statement for which the fee specified in 37 C.F.R. 1.97(c) is required.

Please charge Deposit Account No. 18-1982 in the amount of \$180.00. Two duplicate copies of this sheet are enclosed. The Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

Respectfully submitted,

Barbara E. Kurys, Reg. No. 34,650

Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc. Patent Department Route #202-206 / P.O. Box 6800 Bridgewater, NJ 08807-0800 Telephone (908) 231-2965 Telefax (908) 231-2626

Aventis Docket No. DEAV2002/0050US NP